SCHEMBL2534032

SCHEMBL2534032

COCc1noc(-c2ccc3nc(-n4cccn4)nc(N4CCOCC4)c3n2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
CHRM2 P08172 2/20 0.36
CHRM4 P08173 2/20 0.36
CHRM5 P08912 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
PIK3CA P42336 4/20 0.35
MTOR P42345 1/20 0.35
JAK3 P52333 1/20 0.35
NTRK2 Q16620 1/20 0.35
CAMK2A Q9UQM7 1/20 0.35
EGLN1 Q9GZT9 3/20 0.34
ADORA2A P29274 4/20 0.33
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711450 0.96 LMNA (0.39) HTTLMNACHRM2CHRM4CHRM5
SCHEMBL12220528 0.88 HTT (0.43) HTTLMNAPIK3CAMTORJAK3
SCHEMBL2532500 0.86 LMNA (0.47) HTTLMNAPIK3CAMTORJAK3
SCHEMBL2535247 0.84 CHRM2 (0.36) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2534701 0.73 LMNA (0.48) HTTLMNAPIK3CAMTORJAK3
SCHEMBL12220479 0.72 CD38 (0.33) LMNAPIK3CAMTORKDM4EALDH1A1
SCHEMBL2791040 0.71 PIK3CA (0.40) HTTLMNAPIK3CAMTORJAK3
SCHEMBL2530453 0.71 LMNA (0.52) HTTLMNAPIK3CAMTORJAK3
SCHEMBL12220460 0.71 HTT (0.45) HTTLMNAPIK3CAMTORJAK3
SCHEMBL1711445 0.71 HTT (0.45) HTTLMNAPIK3CAMTORJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
WO-2010037765-A2 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO S.A. (CH) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES PIK3CA, PIK3CD, PIK3CG HTT 3933/4885LMNA 4183/4885CHRM2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.